These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37747899)

  • 21. Amifostine: is there evidence of tumor protection?
    Koukourakis MI
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):18-30. PubMed ID: 14727237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
    Huang R; Yu H; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioprotectants: pharmacology and clinical applications of amifostine.
    Dorr RT
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
    Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
    Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
    Castiglione F; Dalla Mola A; Porcile G
    Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of radiation-induced central nervous system toxicity: a role for amifostine?
    Nieder C; Andratschke NH; Wiedenmann N; Molls M
    Anticancer Res; 2004; 24(6):3803-9. PubMed ID: 15736415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
    Mell LK; Movsas B
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
    Spencer CM; Goa KL
    Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
    Mehta MP
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amifostine-induced fever: case report and review of the literature.
    Boehme S; Wilson DB
    Pharmacotherapy; 2004 Jan; 24(1):155-8. PubMed ID: 14740795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioprotectants: current status and new directions.
    Grdina DJ; Murley JS; Kataoka Y
    Oncology; 2002; 63 Suppl 2():2-10. PubMed ID: 12466639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation-induced craniofacial bone growth inhibition: efficacy of cytoprotection following a fractionated dose regimen.
    La Scala GC; O'Donovan DA; Yeung I; Darko J; Addison PD; Neligan PC; Pang CY; Forrest CR
    Plast Reconstr Surg; 2005 Jun; 115(7):1973-85. PubMed ID: 15923846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypotensive mechanisms of amifostine.
    Ryan SV; Carrithers SL; Parkinson SJ; Skurk C; Nuss C; Pooler PM; Owen CS; Lefer AM; Waldman SA
    J Clin Pharmacol; 1996 Apr; 36(4):365-73. PubMed ID: 8728352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG; Wagner W; Prott FJ
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.